Compare MNDO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNDO | PASG |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | Israel | United States |
| Employees | N/A | 27 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 19.2M |
| IPO Year | 2000 | 2020 |
| Metric | MNDO | PASG |
|---|---|---|
| Price | $1.07 | $4.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 52.7K | ★ 90.5K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 20.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $3.29 |
| 52 Week High | $1.50 | $20.00 |
| Indicator | MNDO | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 65.69 | 41.77 |
| Support Level | $1.02 | $3.94 |
| Resistance Level | $1.24 | $6.01 |
| Average True Range (ATR) | 0.04 | 0.53 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 89.48 | 46.18 |
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.